Home Multimedia Podcasts IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES June 19, 2008 – Interview with Sharon Terry, President and CEO of the Genetic Alliance /wp-content/uploads/2018/09/gc215_6_19_2008.mp3 PodcastsResourcesClinical laboratory techniqueDiagnosisDiagnostic techniquesGenetic testing (Diagnostic technique)Medicine, Diagnosis, and TherapeuticsMolecular technique Also of Interest HIV-Free Hopes Raised by Reservoir-Targeting VLPs Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies Related Media Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Emerging Markets Collaborate to Succeed in Post-Pandemic World Breathing Oxygen Back into the Biological Conversation Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Related Content HIV-Free Hopes Raised by Reservoir-Targeting VLPs Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs